By Stewart A. Factor DO*, Kenneth Wolski MD, Daniel M. Togasaki MD, PhD, Susan Huyck DrPH, Marc Cantillon MD†, T.W. Ho MD‡, Robert A. Hauser MD, MBA and Emmanuelle Pourcher MD
Preladenant is a selective adenosine A2A receptor antagonist under investigation for Parkinson’s disease treatment.